Scancell Begins Research on COVID-19 Vaccine

UK-based immunotherapy developer Scancell has begun research on a DNA-based COVID-19 vaccine.

Scancell said it hopes to use T-cell responses to fight the virus. The company anticipates beginning a phase 1 clinical trial in the first quarter of 2021.

The company said the new vaccine “has the potential to generate protection not only against SARS-CoV-2, but also against new strains of coronavirus that may arise in the future.”